Silk Road Medical to Report Second Quarter 2022 Financial Results on July 26, 2022
Silk Road Medical (Nasdaq: SILK) will report its second quarter 2022 financial results on July 26, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silk Road Medical (Nasdaq: SILK) will report its second quarter 2022 financial results on July 26, 2022, after market close. An audio webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET. The company focuses on reducing stroke risk with its TransCarotid Artery Revascularization (TCAR) procedure, which combines neuroprotection and minimally invasive techniques. For more details, visit their website or register for the event online.
Details
News Market Reaction – SILK
The recorded move for SILK in the trading session of this news was -1.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the second quarter 2022 after market close on Tuesday, July 26, 2022. Company management will host a corresponding audio webcast beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Those interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.silkroadmed.com.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.
Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.